Tissue study for chronic kidney transplant rejection
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study looks at tissue samples from kidney transplant patients who have a specific type of long-term rejection called chronic active humoral rejection (cAMR). It aims to better understand the condition and help future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have received a kidney transplant
- Your kidney function (eGFR) is above 15 ml/min/1.73 sq m at the time cAMR was diagnosed
- You were diagnosed with cAMR after January 1, 2018, based on the 2018 Banff classification
- You are willing to give informed consent to take part
- You have not had a combined transplant (like heart-kidney or kidney-pancreas), and your biopsy does not show other active kidney diseases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new blood test (called TreaT-Assay) to help diagnose acute rejection after a kidney transplant. The goal is to catch rejection earlier and more accurately, so you can get the right treatment faster.
This trial tests a blood test that may help monitor kidney transplant health by detecting signs of rejection earlier. It aims to see if using this blood test can lead to better long-term outcomes for transplant recipients.
This study looks at how memory B cells (a type of immune cell) relate to antibodies against HLA in people waiting for a kidney transplant. It aims to better understand immune responses, which could help improve transplant matching and outcomes.
This study tests a new way to monitor harmful antibodies after a kidney transplant. It may help prevent transplant rejection over time.
This study looks at how the immune system reacts in kidney transplant patients who may be experiencing rejection. It aims to better understand and improve treatment for transplant rejection.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
Hear when a new Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.